| Activation of purified human recombinant acid alpha-glucosidase using resorufin alpha-D-glucopyranoside as substrate after 45 mins relative to basal - BioAssay Summary Pompe disease is a lysosomal storage disease (LSD) caused by a deficiency in the lysosomal enzyme acid alpha-glucosidase. In several LSDs, enzyme inhibitors have been used as small molecule chaperones to facilitate and increase the translocation of mutant protein from the endoplasmic reticulum to the lysosome. Enzyme activators with chaperone activity would be even more desirable as they would more .. |
_ | |
||||||||||||||||||||||||||||||||||||||||||||||||
Target Tested Compound: Description: Title: Evaluation of 2-thioxo-2,3,5,6,7,8-hexahydropyrimido[4,5-d]pyrimidin-4(1H)-one analogues as GAA activators. Abstract: Pompe disease is a lysosomal storage disease (LSD) caused by a deficiency in the lysosomal enzyme acid alpha-glucosidase. In several LSDs, enzyme inhibitors have been used as small molecule chaperones to facilitate and increase the translocation of mutant protein from the endoplasmic reticulum to the lysosome. Enzyme activators with chaperone activity would be even more desirable as they would not inhibit the enzyme after translocation and might potentiate the activity of the enzyme that is successfully translocated. Herein we report our initial findings of a new series of acid alpha-glucosidase activators. (PMID: 20206419) Categorized Comment ChEMBL Assay Type: Binding ChEMBL Assay Data Source: Scientific Literature ChEMBL Target ID: 10977 ChEMBL target type: Target is a single protein chain Result Definitions
Data Table (Concise) Classification
PageFrom: |
||||||||||||||||||||||||||||||||||||||||||||||||||